After surviving cancer, what about late life effects of the cure?

The widely used chemotherapeutic cisplatin causes ototoxicity as late‐term side effect. In this issue, Benkafadar et al (2017) decipher the mechanism of cisplatin‐induced ototoxicity and provide evidence that transient inhibition of p53 ameliorates ototoxicity without influencing chemotherapeutic ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Nonnekens, Julie, Hoeijmakers, Jan HJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210081/
https://www.ncbi.nlm.nih.gov/pubmed/27852619
http://dx.doi.org/10.15252/emmm.201607062
_version_ 1782490834599411712
author Nonnekens, Julie
Hoeijmakers, Jan HJ
author_facet Nonnekens, Julie
Hoeijmakers, Jan HJ
author_sort Nonnekens, Julie
collection PubMed
description The widely used chemotherapeutic cisplatin causes ototoxicity as late‐term side effect. In this issue, Benkafadar et al (2017) decipher the mechanism of cisplatin‐induced ototoxicity and provide evidence that transient inhibition of p53 ameliorates ototoxicity without influencing chemotherapeutic efficacy. These findings may open exciting perspectives for reducing (late‐term) side effects of cancer treatment.
format Online
Article
Text
id pubmed-5210081
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52100812017-01-05 After surviving cancer, what about late life effects of the cure? Nonnekens, Julie Hoeijmakers, Jan HJ EMBO Mol Med News & Views The widely used chemotherapeutic cisplatin causes ototoxicity as late‐term side effect. In this issue, Benkafadar et al (2017) decipher the mechanism of cisplatin‐induced ototoxicity and provide evidence that transient inhibition of p53 ameliorates ototoxicity without influencing chemotherapeutic efficacy. These findings may open exciting perspectives for reducing (late‐term) side effects of cancer treatment. John Wiley and Sons Inc. 2016-11-16 2017-01 /pmc/articles/PMC5210081/ /pubmed/27852619 http://dx.doi.org/10.15252/emmm.201607062 Text en © 2016 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the Creative Commons Attribution 4.0 (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle News & Views
Nonnekens, Julie
Hoeijmakers, Jan HJ
After surviving cancer, what about late life effects of the cure?
title After surviving cancer, what about late life effects of the cure?
title_full After surviving cancer, what about late life effects of the cure?
title_fullStr After surviving cancer, what about late life effects of the cure?
title_full_unstemmed After surviving cancer, what about late life effects of the cure?
title_short After surviving cancer, what about late life effects of the cure?
title_sort after surviving cancer, what about late life effects of the cure?
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210081/
https://www.ncbi.nlm.nih.gov/pubmed/27852619
http://dx.doi.org/10.15252/emmm.201607062
work_keys_str_mv AT nonnekensjulie aftersurvivingcancerwhataboutlatelifeeffectsofthecure
AT hoeijmakersjanhj aftersurvivingcancerwhataboutlatelifeeffectsofthecure

Ejemplares similares